Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Stable asthma medications: No change in asthma medications for the past 2 months:
‣ Use of medium or high dose inhaled corticosteroids (ICS) AND
⁃ Use of an additional asthma controller medication.
• Baseline poor or uncontrolled asthma.
• Evidence of asthma demonstrated by either bronchodilator reversibility (either at screening or by historical evidence) or methacholine responsiveness (by historical evidence).
• Agreement to adhere to Lifestyle Considerations throughout study duration.